Background
Pentatrichomonas hominis
is a flagellated protozoan that inhabits the large intestine of humans. Although several protozoans have been proposed to have a role in cancer progression, little is known about the epidemiology of
P. hominis
infection in cancer patients.
Methods
To determine the prevalence of
P. hominis
in patients with digestive system malignancies, we collected 195 and 142 fecal samples from gastrointestinal cancer patients and residents without any complaints related to the digestive system, respectively. Each sample was detected for the presence of
P. hominis
by nested PCR amplifying the internal transcribed spacer (ITS) region and partial
18S
rRNA gene.
Results
A significantly higher prevalence of
P. hominis
was found in cancer patients than that in the control population (41.54
vs
9.15%,
χ
2
= 42.84,
df
= 1,
P
< 0.001), resulting in a 6.75-fold risk of gastrointestinal cancers (OR: 6.75, 95% CI: 3.55–12.83,
P
< 0.001). The highest prevalence of
P. hominis
infection was detected in small intestine cancer patients (60%, OR: 14.88, 95% CI: 0.82–4.58,
P
= 0.009) followed by liver (57.14%,
χ
2
= 10.82,
df
= 1,
P
= 0.001) and stomach cancer patients (45.1%,
χ
2
= 31.95,
df
= 1,
P
< 0.001). In addition, phylogenetic analysis provided some evidence supporting that human
P. hominis
infection might derive from animal sources.
Conclusions
To our knowledge, this study is the first report presenting the high association between
P. hominis
and gastrointestinal cancers. Nevertheless, whether there is any possible pathological role of
P. hominis
infection in cancer patients needs to be further elucidated.